<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 AmerisourceBergen ABC today announced a new organizational 
 structure designed to further align the organization to its customer 
 needs in a more seamless and unified way, while supporting corporate 
 strategy and accelerating growth. The Company's customer-facing 
 offerings will now be aligned under two groups:
 
 <ul xmlns="http://www.w3.org/1999/xhtml">
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Pharmaceutical Distribution and Strategic Global Sourcing – 
 Will be led by Group President Robert P. Mauch, Pharm.D., Ph.D., and 
 includes the Company's services to retail chain and independent 
 pharmacies, health systems, physician practices and alternate care 
 sites as well as AmerisourceBergen's sourcing, repackaging and 
 specialty pharmacy capabilities. Peyton Howell will assume a new role 
 as President, Health Systems, Physician Practices and Strategic Health 
 Solutions
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Global Commercialization Services and Animal Health – Will be 
 led by Group President James F. Cleary, Jr., and includes the 
 Company's solutions for product commercialization and patient access, 
 as well as international development and animal health
 </li>
 </ul>
 
 "AmerisourceBergen has assembled and built best-in-class capabilities to 
 support every stage of pharmaceutical care, with the goal of ensuring 
 access to medicines that create healthier futures for patients," said 
 Steven H. Collis, Chairman, President and Chief Executive Officer of 
 AmerisourceBergen. "This strategy has served as the engine of 
 AmerisourceBergen's success and we are now evolving our organization to 
 capitalize on our unique portfolio of services. Our vision is to 
 accelerate AmerisourceBergen's corporate growth by further aligning our 
 operating model to the dynamic customer needs in the health and 
 pharmaceutical industry."
 
 
 For financial reporting purposes, AmerisourceBergen operations will 
 continue to be comprised of the Pharmaceutical Distribution Services 
 reportable segment and Other.
 
 
 AmerisourceBergen has also formed a new management committee to enable 
 quicker, cross-functional decision-making. This senior executive group 
 includes:
 
 <ul xmlns="http://www.w3.org/1999/xhtml">
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Steven H. Collis, Chairman, President and Chief Executive Officer
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 John G. Chou, Chief Legal and Business Officer, who will now have 
 responsibility for legal and regulatory affairs along with strategy, 
 innovation and business development led by Sun Park, Executive Vice 
 President, Strategy and Business Development, as well as information 
 technology led by Dale Danilewitz, Executive Vice President and Chief 
 Information Officer
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Gina K. Clark, Chief Communications and Administration Officer, who 
 will now have responsibility for marketing and communication and 
 corporate citizenship and sustainability along with human resources 
 led by Kathy H. Gaddes, Executive Vice President and Chief Human 
 Resources Officer, government affairs led by Rita Norton, Senior Vice 
 President, Government Affairs and Public Policy
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 James F. Cleary, Jr., Group President, Global Commercialization 
 Services and Animal Health
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Tim G. Guttman, Chief Financial Officer
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Robert P. Mauch, Group President, Pharmaceutical Distribution and 
 Strategic Global Sourcing
 </li>
 </ul>
 
 After 10 years of service with a track record of exceptional integrity, 
 leadership and performance, James Frary, previously Executive Vice 
 President and President, AmerisourceBergen Specialty Group (ABSG), has 
 decided to pursue new opportunities outside of AmerisourceBergen. Frary 
 will be available to support the organization over the next few months 
 as he transitions from his role.
 
 
 "We are better positioned to meet the needs of the marketplace because 
 of James' leadership and I'm truly grateful for his guidance and 
 partnership over the past decade," said Collis. "We will carry that 
 industry leadership into our new management committee structure. This 
 group will be singularly focused on aligning every aspect of 
 AmerisourceBergen to our purpose, corporate strategy and continued 
 growth. We believe this next evolution of AmerisourceBergen will enable 
 the Company to be more nimble and effective, actively supporting our 
 customers as they grow and unlock the full value of their businesses."
 
 
 About AmerisourceBergen
 
 
 AmerisourceBergen provides pharmaceutical products, value-driving 
 services and business solutions that improve access to care. Tens of 
 thousands of healthcare providers, veterinary practices and livestock 
 producers trust us as their partner in the pharmaceutical supply chain. 
 Global manufacturers depend on us for services that drive commercial 
 success for their products. Through our daily work—and powered by our 
 19,000 associates—we are united in our responsibility to create 
 healthier futures. AmerisourceBergen is ranked #11 on the Fortune 500, 
 with more than $145 billion in annual revenue. The company is 
 headquartered in Valley Forge, Pa. and has a presence in 50+ countries. 
 Learn more at amerisourcebergen.com.
 
 
 AmerisourceBergen&#39;s Cautionary Note Regarding Forward-Looking 
 Statements
 
 
 Certain of the statements contained in this press release are 
 &#34;forward-looking statements&#34; within the meaning of Section 27A of the 
 Securities Act of 1933 and Section 21E of the Securities Exchange Act of 
 1934. Words such as &#34;expect,&#34; &#34;likely,&#34; &#34;outlook,&#34; &#34;forecast,&#34; &#34;would,&#34; 
 &#34;could,&#34; &#34;should,&#34; &#34;can,&#34; &#34;will,&#34; &#34;project,&#34; &#34;intend,&#34; &#34;plan,&#34; 
 &#34;continue,&#34; &#34;sustain,&#34; &#34;synergy,&#34; &#34;on track,&#34; &#34;believe,&#34; &#34;seek,&#34; 
 &#34;estimate,&#34; &#34;anticipate,&#34; &#34;may,&#34; &#34;possible,&#34; &#34;assume,&#34; variations of 
 such words, and similar expressions are intended to identify such 
 forward-looking statements. These statements are based on management&#39;s 
 current expectations and are subject to uncertainty and change in 
 circumstances. These statements are not guarantees of future performance 
 and are based on assumptions that could prove incorrect or could cause 
 actual results to vary materially from those indicated. Among the 
 factors that could cause actual results to differ materially from those 
 projected, anticipated, or implied are the following: unfavorable trends 
 in brand and generic pharmaceutical pricing, including in rate or 
 frequency of price inflation or deflation; competition and industry 
 consolidation of both customers and suppliers resulting in increasing 
 pressure to reduce prices for our products and services; changes in 
 pharmaceutical market growth rates; substantial defaults in payment, 
 material reduction in purchases by or the loss, bankruptcy or insolvency 
 of a major customer; changes to the customer or supplier mix; the 
 retention of key customer or supplier relationships under less favorable 
 economics or the adverse resolution of any contract or other dispute 
 with customers or suppliers; changes to customer or supplier payment 
 terms; the disruption of AmerisourceBergen&#39;s cash flow and ability to 
 return value to its stockholders in accordance with its past practices; 
 risks associated with the strategic, long-term relationship 
 between Walgreens Boots Alliance, Inc. and AmerisourceBergen, including 
 with respect to the pharmaceutical distribution agreement and/or the 
 global sourcing arrangement; changes in the United States healthcare and 
 regulatory environment, including changes that could impact prescription 
 drug reimbursement under Medicare and Medicaid; increasing governmental 
 regulations regarding the pharmaceutical supply channel and 
 pharmaceutical compounding; federal and state government enforcement 
 initiatives to detect and prevent suspicious orders of controlled 
 substances and the diversion of controlled substances; federal and state 
 prosecution of alleged violations of related laws and regulations, and 
 any related litigation, including shareholder derivative lawsuits or 
 other disputes relating to our distribution of controlled substances; 
 increased federal scrutiny and qui tam litigation for alleged violations 
 of fraud and abuse laws and regulations and/or any other laws and 
 regulations governing the marketing, sale, purchase and/or dispensing of 
 pharmaceutical products or services and any related litigation; material 
 adverse resolution of pending legal proceedings; declining reimbursement 
 rates for pharmaceuticals; the acquisition of businesses that do not 
 perform as expected, or that are difficult to integrate or control, 
 including the integration of PharMEDium, or the inability to capture all 
 of the anticipated synergies related thereto; regulatory action in 
 connection with the production, labeling or packaging of products 
 compounded by our compounded sterile preparations (CSP) business; 
 declining economic conditions in the United States and abroad; financial 
 market volatility and disruption; the loss, bankruptcy or insolvency of 
 a major supplier; interest rate and foreign currency exchange rate 
 fluctuations; managing foreign expansion, including non-compliance with 
 the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic 
 sanctions and import laws and regulations; malfunction, failure or 
 breach of sophisticated information systems to operate as designed; 
 risks generally associated with data privacy regulation and the 
 international transfer of personal data; changes in tax laws or 
 legislative initiatives that could adversely 
 affect AmerisourceBergen&#39;s tax positions and/or AmerisourceBergen's tax 
 liabilities or adverse resolution of challenges 
 to AmerisourceBergen&#39;s tax positions; natural disasters or other 
 unexpected events that affect AmerisourceBergen&#39;s operations; the 
 impairment of goodwill or other intangible assets, resulting in a charge 
 to earnings; and other economic, business, competitive, legal, tax, 
 regulatory and/or operational factors 
 affecting AmerisourceBergen&#39;s business generally. Certain additional 
 factors that management believes could cause actual outcomes and results 
 to differ materially from those described in forward-looking statements 
 are set forth (i) in Item 1A (Risk Factors) in the Company's Annual 
 Report on Form 10-K for the fiscal year ended September 30, 2016 and 
 elsewhere in that report and (ii) in other reports filed by the Company 
 pursuant to the Securities Exchange Act.
 
 
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170619005336r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170619005336/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170619005336/en/</a></body></html>

Press Releases

AmerisourceBergen Structures Operating Model and Executive Leadership Team to Offer a More Cohesive and Unified Customer Experience, Enhance Growth and Drive Long-Term Value 


RISE with SAP and HPE GreenLake enables Danfoss to run its mission-critical SAP workloads on its energy efficient and sovereign modular data centers, with flexibility, scalability and cost-efficiency


Danfoss, the

Danfoss Selects RISE with SAP and HPE GreenLake to Accelerate Sustainable Cloud Journey



Suzano Ventures, the corporate venture capital arm of Suzano, the world&#39;s largest market pulp producer, is funding up to US$5 million for Canadian startup, Bioform Technologies




Bioform&#39;s innovative materials,

Suzano Ventures invests up to US$5 million into Bioform Technologies to further develop bio-based plastic alternatives

GWRE


Guidewire (NYSE:GWRE) launched its first-ever DEVSummit, a two-day event designed to unite, educate, and energize the global Guidewire development community. At DEVSummit 2024, attendees will hear mainstage keynote

Guidewire Launches DEVSummit


SES is now deploying O3b mPOWER services worldwide, delivering high throughput, flexibility and low latency


SES announced today that O3b mPOWER, its second-generation software-enabled satellite system, is now

SES&#39;s O3b mPOWER System Starts Providing High-performance Connectivity Services


In accordance with the Listing Rules, please see the transcript below relating to the above, for release to the market.


This announcement was approved and authorised for release by Woodside&#39;s Disclosure

Woodside Energy Group Ltd Annual General Meeting Address by Chair Richard Goyder and CEO Meg O&#39;Neill


Financial Highlights:



Q124 consolidated revenue US$121.28 million, compared with US$99.99 million in the year-ago quarter



Q124 consolidated net income US$18.21 million; Basic and Fully diluted after-tax EPS